U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1PD-L1 Inhibitor – – New Indication Marks Second FDA Approval for Trodelvy in 2021 – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of Trodelvy ® for use in adult patients with locally adv...
Source: investingnews.com